| Lindsay Eliza Gracey, AUD | |
|
660 Glades Rd Ste 400, Boca Raton, FL 33431-6469 | |
| (561) 750-2100 | |
| (561) 750-0889 |
| Full Name | Lindsay Eliza Gracey |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 660 Glades Rd Ste 400, Boca Raton, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669123865 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AY1934 (Florida) | Primary |
| Provider Name | South Florida Ent Associates Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184625733 PECOS PAC ID: 4587556923 Enrollment ID: O20040329001213 |
News Archive
Sentrx, a leading provider of drug safety services to the life sciences industry, has achieved Gold Partner status in the Oracle PartnerNetwork. Sentrx will provide life sciences companies with support for Oracle clinical solutions, emphasizing its expertise in drug safety systems, safety data management and adverse event reporting software, processes and consulting expertise.
Up to eight out of ten patients with a brain disorder remain untreated or inadequately treated. But what is the best practice - and above all, most cost effective - healthcare interventions to bridge the treatment gap? This was the focus of the European Brain Council's study entitled The Value of Treatment which was discussed at the Congress of the European Academy of Neurology in Lisbon.
Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.
A vaccine against one of the most dangerous hospital germs may soon be available. Scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universität Berlin have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile.
› Verified 3 days ago
| Provider Name | Wave Audiology |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1265188817 PECOS PAC ID: 0547657058 Enrollment ID: O20220503000508 |
News Archive
Sentrx, a leading provider of drug safety services to the life sciences industry, has achieved Gold Partner status in the Oracle PartnerNetwork. Sentrx will provide life sciences companies with support for Oracle clinical solutions, emphasizing its expertise in drug safety systems, safety data management and adverse event reporting software, processes and consulting expertise.
Up to eight out of ten patients with a brain disorder remain untreated or inadequately treated. But what is the best practice - and above all, most cost effective - healthcare interventions to bridge the treatment gap? This was the focus of the European Brain Council's study entitled The Value of Treatment which was discussed at the Congress of the European Academy of Neurology in Lisbon.
Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.
A vaccine against one of the most dangerous hospital germs may soon be available. Scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universität Berlin have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsay Eliza Gracey, AUD 660 Glades Rd Ste 400, Boca Raton, FL 33431-6469 Ph: (561) 750-2100 | Lindsay Eliza Gracey, AUD 660 Glades Rd Ste 400, Boca Raton, FL 33431-6469 Ph: (561) 750-2100 |
News Archive
Sentrx, a leading provider of drug safety services to the life sciences industry, has achieved Gold Partner status in the Oracle PartnerNetwork. Sentrx will provide life sciences companies with support for Oracle clinical solutions, emphasizing its expertise in drug safety systems, safety data management and adverse event reporting software, processes and consulting expertise.
Up to eight out of ten patients with a brain disorder remain untreated or inadequately treated. But what is the best practice - and above all, most cost effective - healthcare interventions to bridge the treatment gap? This was the focus of the European Brain Council's study entitled The Value of Treatment which was discussed at the Congress of the European Academy of Neurology in Lisbon.
Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.
A vaccine against one of the most dangerous hospital germs may soon be available. Scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universität Berlin have developed a substance that elicits an immune response against the gut bacterium Clostridium difficile.
› Verified 3 days ago
Kathryn F Jackson, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1601 Clint Moore Rd, Suite 105, Boca Raton, FL 33487 Phone: 561-393-9150 | |
Dr. Meredith Anderson Buemi, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 7900 Glades Road, Suite 340, Boca Raton, FL 33433 Phone: 561-353-7377 | |
Active Life Hearing Audiologist Medicare: Medicare Enrolled Practice Location: 8903 Glades Rd Ste A14, Boca Raton, FL 33434 Phone: 561-221-0450 Fax: 954-827-0591 | |
Diana Barreneche, Inc Audiologist Medicare: Medicare Enrolled Practice Location: 7100 W Camino Real Ste 200, Boca Raton, FL 33433 Phone: 561-674-2859 Fax: 561-571-0316 | |
Labyrinth Audiology Audiologist Medicare: Medicare Enrolled Practice Location: 1500 Nw 10th Ave, Suite 104, Boca Raton, FL 33486 Phone: 561-807-7873 Fax: 561-807-7947 | |
Erin Elizabeth Anderson, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1601 Clint Moore Rd, Suite 105, Boca Raton, FL 33487 Phone: 561-393-9150 | |
Erin Rae Cocchiola, AU. D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1601 Clint Moore Rd, #105, Boca Raton, FL 33487 Phone: 561-939-0173 |